{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:04:05Z","timestamp":1791266645897,"version":"4.1.0"},"reference-count":171,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41575-026-01175-y","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T10:28:40Z","timestamp":1770892120000},"page":"493-509","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Germline mutations and somatic mosaicism in steatotic liver diseases and related liver carcinogenesis"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0475-3934","authenticated-orcid":false,"given":"Eric","family":"Tr\u00e9po","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5687-0334","authenticated-orcid":false,"given":"Jessica","family":"Zucman-Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Charles","family":"Nault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"1175_CR1","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/S0140-6736(24)01811-7","volume":"404","author":"M Israelsen","year":"2024","unstructured":"Israelsen, M., Francque, S., Tsochatzis, E. A. & Krag, A. Steatotic liver disease. Lancet 404, 1761\u20131778 (2024).","journal-title":"Lancet"},{"key":"1175_CR2","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41571-023-00825-3","volume":"20","author":"AG Singal","year":"2023","unstructured":"Singal, A. G., Kanwal, F. & Llovet, J. M. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat. Rev. Clin. Oncol. 20, 864\u2013884 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1175_CR3","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41575-024-01022-y","volume":"22","author":"N Torp","year":"2025","unstructured":"Torp, N., Israelsen, M. & Krag, A. The steatotic liver disease burden paradox: unravelling the key role of alcohol. Nat. Rev. Gastroenterol. Hepatol. 22, 281\u2013292 (2025).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1175_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","volume":"399","author":"TH Karlsen","year":"2022","unstructured":"Karlsen, T. H. et al. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 399, 61\u2013116 (2022).","journal-title":"Lancet"},{"key":"1175_CR5","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 79, 1542\u20131556 (2023).","journal-title":"J. Hepatol."},{"key":"1175_CR6","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi, Z. M. et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 77, 1335\u20131347 (2023).","journal-title":"Hepatology"},{"key":"1175_CR7","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi, K. et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 7, 851\u2013861 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1175_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/ng.488","volume":"42","author":"C Tian","year":"2010","unstructured":"Tian, C., Stokowski, R. P., Kershenobich, D., Ballinger, D. G. & Hinds, D. A. Variant in PNPLA3 is associated with alcoholic liver disease. Nat. Genet. 42, 21\u201323 (2010).","journal-title":"Nat. Genet."},{"key":"1175_CR9","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/hep.20466","volume":"40","author":"JD Browning","year":"2004","unstructured":"Browning, J. D. et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40, 1387\u20131395 (2004).","journal-title":"Hepatology"},{"key":"1175_CR10","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/hep.32774","volume":"77","author":"TC-F Yip","year":"2023","unstructured":"Yip, T. C.-F. et al. Geographical similarity and differences in the burden and genetic predisposition of NAFLD. Hepatology 77, 1404\u20131427 (2023).","journal-title":"Hepatology"},{"key":"1175_CR11","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.jhep.2020.02.020","volume":"72","author":"E Tr\u00e9po","year":"2020","unstructured":"Tr\u00e9po, E. & Valenti, L. Update on NAFLD genetics: from new variants to the clinic. J. Hepatol. 72, 1196\u20131209 (2020).","journal-title":"J. Hepatol."},{"key":"1175_CR12","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver EASL clinical practical guidelines: management of alcoholic liver disease. J. Hepatol. 57, 399\u2013420 (2012).","DOI":"10.1016\/j.jhep.2012.04.004"},{"key":"1175_CR13","unstructured":"European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol. 81, 492\u2013542 (2024)."},{"key":"1175_CR14","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41586-024-07316-0","volume":"629","author":"EV Minikel","year":"2024","unstructured":"Minikel, E. V., Painter, J. L., Dong, C. C. & Nelson, M. R. Refining the impact of genetic evidence on clinical success. Nature 629, 624\u2013629 (2024).","journal-title":"Nature"},{"key":"1175_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-024-00794-y","author":"CS Gallagher","year":"2024","unstructured":"Gallagher, C. S., Ginsburg, G. S. & Musick, A. Biobanking with genetics shapes precision medicine and global health. Nat. Rev. Genet. https:\/\/doi.org\/10.1038\/s41576-024-00794-y (2024).","journal-title":"Nat. Rev. Genet."},{"key":"1175_CR16","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41588-022-01078-z","volume":"54","author":"M Vujkovic","year":"2022","unstructured":"Vujkovic, M. et al. A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. Nat. Genet. 54, 761\u2013771 (2022).","journal-title":"Nat. Genet."},{"key":"1175_CR17","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1038\/s41588-023-01497-6","volume":"55","author":"Y Chen","year":"2023","unstructured":"Chen, Y. et al. Genome-wide association meta-analysis identifies 17 loci associated with nonalcoholic fatty liver disease. Nat. Genet. 55, 1640\u20131650 (2023).","journal-title":"Nat. Genet."},{"key":"1175_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16211","volume":"45","author":"C Galvanin","year":"2025","unstructured":"Galvanin, C., Buch, S., Nahon, P. & Tr\u00e9po, E. PNPLA3 in alcohol-related liver disease. Liver Int. 45, e16211 (2025).","journal-title":"Liver Int."},{"key":"1175_CR19","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/s41588-024-01720-y","volume":"56","author":"J Ghouse","year":"2024","unstructured":"Ghouse, J. et al. Integrative common and rare variant analyses provide insights into the genetic architecture of liver cirrhosis. Nat. Genet. 56, 827\u2013837 (2024).","journal-title":"Nat. Genet."},{"key":"1175_CR20","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1097\/HEP.0000000000000604","volume":"79","author":"BP Lee","year":"2024","unstructured":"Lee, B. P., Dodge, J. L. & Terrault, N. A. National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature. Hepatology 79, 666\u2013673 (2024).","journal-title":"Hepatology"},{"key":"1175_CR21","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S2468-1253(23)00443-0","volume":"9","author":"M Israelsen","year":"2024","unstructured":"Israelsen, M. et al. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study. Lancet Gastroenterol. Hepatol. 9, 218\u2013228 (2024).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1175_CR22","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1038\/s41591-024-03284-0","volume":"30","author":"O Jamialahmadi","year":"2024","unstructured":"Jamialahmadi, O. et al. Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease. Nat. Med. 30, 3614\u20133623 (2024).","journal-title":"Nat. Med."},{"key":"1175_CR23","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","volume":"40","author":"S Romeo","year":"2008","unstructured":"Romeo, S. et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 40, 1461\u20131465 (2008).","journal-title":"Nat. Genet."},{"key":"1175_CR24","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jhep.2016.03.011","volume":"65","author":"E Tr\u00e9po","year":"2016","unstructured":"Tr\u00e9po, E., Romeo, S., Zucman-Rossi, J. & Nahon, P. PNPLA3 gene in liver diseases. J. Hepatol. 65, 399\u2013412 (2016).","journal-title":"J. Hepatol."},{"key":"1175_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12863-015-0255-3","volume":"16","author":"AC Pontoriero","year":"2015","unstructured":"Pontoriero, A. C. et al. Influence of ethnicity on the distribution of genetic polymorphisms associated with risk of chronic liver disease in South American populations. BMC Genet. 16, 93 (2015).","journal-title":"BMC Genet."},{"key":"1175_CR26","doi-asserted-by":"publisher","first-page":"9521","DOI":"10.1073\/pnas.1901974116","volume":"116","author":"S BasuRay","year":"2019","unstructured":"BasuRay, S., Wang, Y., Smagris, E., Cohen, J. C. & Hobbs, H. H. Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis. Proc. Natl Acad. Sci. USA 116, 9521\u20139526 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1175_CR27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2312291121","volume":"121","author":"A Das","year":"2024","unstructured":"Das, A. et al. The ubiquitin E3 ligase BFAR promotes degradation of PNPLA3. Proc. Natl. Acad. Sci. USA 121, e2312291121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1175_CR28","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/hep.27242","volume":"61","author":"E Smagris","year":"2015","unstructured":"Smagris, E. et al. Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology 61, 108\u2013118 (2015).","journal-title":"Hepatology"},{"key":"1175_CR29","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1093\/hmg\/ddu121","volume":"23","author":"C Pirazzi","year":"2014","unstructured":"Pirazzi, C. et al. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Hum. Mol. Genet. 23, 4077\u20134085 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"1175_CR30","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jhep.2022.08.022","volume":"78","author":"J Park","year":"2023","unstructured":"Park, J. et al. IL-6\/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease. J. Hepatol. 78, 45\u201356 (2023).","journal-title":"J. Hepatol."},{"key":"1175_CR31","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/ng.2901","volume":"46","author":"J Kozlitina","year":"2014","unstructured":"Kozlitina, J. et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 46, 352\u2013356 (2014).","journal-title":"Nat. Genet."},{"key":"1175_CR32","doi-asserted-by":"publisher","first-page":"10659","DOI":"10.1074\/jbc.M116.719955","volume":"291","author":"E Smagris","year":"2016","unstructured":"Smagris, E., Gilyard, S., BasuRay, S., Cohen, J. C. & Hobbs, H. H. Inactivation of Tm6sf2, a gene defective in fatty liver disease, impairs lipidation but not secretion of very low density lipoproteins. J. Biol. Chem. 291, 10659\u201310676 (2016).","journal-title":"J. Biol. Chem."},{"key":"1175_CR33","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","volume":"150","author":"RM Mancina","year":"2016","unstructured":"Mancina, R. M. et al. The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent. Gastroenterology 150, 1219\u20131230.e6 (2016).","journal-title":"Gastroenterology"},{"key":"1175_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1001324","volume":"7","author":"EK Speliotes","year":"2011","unstructured":"Speliotes, E. K. et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 7, e1001324 (2011).","journal-title":"PLoS Genet."},{"key":"1175_CR35","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","volume":"378","author":"NS Abul-Husn","year":"2018","unstructured":"Abul-Husn, N. S. et al. A protein-truncating HSD17B13 variant and protection from chronic liver disease. N. Engl. J. Med. 378, 1096\u20131106 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1175_CR36","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/hep.30350","volume":"69","author":"Y Ma","year":"2019","unstructured":"Ma, Y. et al. 17-Beta hydroxysteroid dehydrogenase 13 is a hepatic retinol dehydrogenase associated with histological features of nonalcoholic fatty liver disease. Hepatology 69, 1504\u20131519 (2019).","journal-title":"Hepatology"},{"key":"1175_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1008629","volume":"16","author":"CA Emdin","year":"2020","unstructured":"Emdin, C. A. et al. A missense variant in mitochondrial amidoxime reducing component 1 gene and protection against liver disease. PLoS Genet. 16, e1008629 (2020).","journal-title":"PLoS Genet."},{"key":"1175_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1011179","volume":"20","author":"E Smagris","year":"2024","unstructured":"Smagris, E. et al. Divergent role of mitochondrial amidoxime reducing component 1 (MARC1) in human and mouse. PLoS Genet. 20, e1011179 (2024).","journal-title":"PLoS Genet."},{"key":"1175_CR39","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1111\/liv.15857","volume":"44","author":"T Dutta","year":"2024","unstructured":"Dutta, T. et al. Mitochondrial amidoxime-reducing component 1 p.Ala165Thr increases protein degradation mediated by the proteasome. Liver Int. 44, 1219\u20131232 (2024).","journal-title":"Liver Int."},{"key":"1175_CR40","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000365","volume":"8","author":"AK Jones","year":"2024","unstructured":"Jones, A. K. et al. mARC1 in MASLD: modulation of lipid accumulation in human hepatocytes and adipocytes. Hepatol. Commun. 8, e0365 (2024).","journal-title":"Hepatol. Commun."},{"key":"1175_CR41","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jhep.2022.09.020","volume":"78","author":"B Fromenty","year":"2023","unstructured":"Fromenty, B. & Roden, M. Mitochondrial alterations in fatty liver diseases. J. Hepatol. 78, 415\u2013429 (2023).","journal-title":"J. Hepatol."},{"key":"1175_CR42","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1136\/gutjnl-2012-302962","volume":"62","author":"CJ Pirola","year":"2013","unstructured":"Pirola, C. J. et al. Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. Gut 62, 1356\u20131363 (2013).","journal-title":"Gut"},{"key":"1175_CR43","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s42255-021-00518-0","volume":"4","author":"RM Mancina","year":"2022","unstructured":"Mancina, R. M. et al. PSD3 downregulation confers protection against fatty liver disease. Nat. Metab. 4, 60\u201375 (2022).","journal-title":"Nat. Metab."},{"key":"1175_CR44","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1056\/NEJMc1804027","volume":"379","author":"J Kozlitina","year":"2018","unstructured":"Kozlitina, J., Stender, S., Hobbs, H. H. & Cohen, J. C. HSD17B13 and chronic liver disease in Blacks and Hispanics. N. Engl. J. Med. 379, 1876\u20131877 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1175_CR45","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41586-021-04103-z","volume":"599","author":"JD Backman","year":"2021","unstructured":"Backman, J. D. et al. Exome sequencing and analysis of 454,787 UK Biobank participants. Nature 599, 628\u2013634 (2021).","journal-title":"Nature"},{"key":"1175_CR46","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1056\/NEJMoa2117872","volume":"387","author":"N Verweij","year":"2022","unstructured":"Verweij, N. et al. Germline mutations in CIDEB and protection against liver disease. N. Engl. J. Med. 387, 332\u2013344 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1175_CR47","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41586-021-03855-y","volume":"597","author":"Q Wang","year":"2021","unstructured":"Wang, Q. et al. Rare variant contribution to human disease in 281,104 UK Biobank exomes. Nature 597, 527\u2013532 (2021).","journal-title":"Nature"},{"key":"1175_CR48","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/ng.3855","volume":"49","author":"S Stender","year":"2017","unstructured":"Stender, S. et al. Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nat. Genet. 49, 842\u2013847 (2017).","journal-title":"Nat. Genet."},{"key":"1175_CR49","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.34221","volume":"5","author":"H-S Kim","year":"2022","unstructured":"Kim, H.-S. et al. Synergistic associations of PNPLA3 I148M variant, alcohol intake, and obesity with risk of cirrhosis, hepatocellular carcinoma, and mortality. JAMA Netw. Open 5, e2234221 (2022).","journal-title":"JAMA Netw. Open"},{"key":"1175_CR50","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.jhep.2024.06.036","volume":"81","author":"D Marti-Aguado","year":"2024","unstructured":"Marti-Aguado, D. et al. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease. J. Hepatol. 81, 930\u2013940 (2024).","journal-title":"J. Hepatol."},{"key":"1175_CR51","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.3350\/cmh.2025.0159","volume":"31","author":"O Jamialahmadi","year":"2025","unstructured":"Jamialahmadi, O. et al. Genome-wide interaction study with BMI identifies CYP7A1 and GIPR as genetic modulators of MASLD. Clin. Mol. Hepatol. 31, 1252\u20131268\u00a0(2025).","journal-title":"Clin. Mol. Hepatol."},{"key":"1175_CR52","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1146\/annurev-physiol-061121-040048","volume":"84","author":"H Ogawa","year":"2022","unstructured":"Ogawa, H., Horitani, K., Izumiya, Y. & Sano, S. Somatic mosaicism in biology and disease. Annu. Rev. Physiol. 84, 113\u2013133 (2022).","journal-title":"Annu. Rev. Physiol."},{"key":"1175_CR53","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cell.2020.06.024","volume":"182","author":"J Vijg","year":"2020","unstructured":"Vijg, J. & Dong, X. Pathogenic mechanisms of somatic mutation and genome mosaicism in aging. Cell 182, 12\u201323 (2020).","journal-title":"Cell"},{"key":"1175_CR54","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/humu.20549","volume":"28","author":"S Aretz","year":"2007","unstructured":"Aretz, S. et al. Somatic APC mosaicism: a frequent cause of familial adenomatous polyposis (FAP). Hum. Mutat. 28, 985\u2013992 (2007).","journal-title":"Hum. Mutat."},{"key":"1175_CR55","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1210\/jc.2003-031225","volume":"89","author":"S Lumbroso","year":"2004","unstructured":"Lumbroso, S., Paris, F. & Sultan, C. Activating Gs\u03b1 mutations: analysis of 113 patients with signs of McCune\u2013Albright syndrome \u2014 a European Collaborative Study. J. Clin. Endocrinol. Metab. 89, 2107\u20132113 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1175_CR56","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jhep.2011.07.018","volume":"56","author":"JC Nault","year":"2012","unstructured":"Nault, J. C. et al. GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. J. Hepatol.\u00a056, 184\u2013191 (2012).","journal-title":"J. Hepatol."},{"key":"1175_CR57","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1056\/NEJM199112123252403","volume":"325","author":"LS Weinstein","year":"1991","unstructured":"Weinstein, L. S. et al. Activating mutations of the stimulatory G protein in the McCune\u2013Albright syndrome. N. Engl. J. Med. 325, 1688\u20131695 (1991).","journal-title":"N. Engl. J. Med."},{"key":"1175_CR58","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1056\/NEJMoa1104017","volume":"365","author":"MJ Lindhurst","year":"2011","unstructured":"Lindhurst, M. J. et al. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N. Engl. J. Med. 365, 611\u2013619 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1175_CR59","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1158\/2159-8290.CD-20-1809","volume":"11","author":"TZ Hirsch","year":"2021","unstructured":"Hirsch, T. Z. et al. Integrated genomic analysis identifies driver genes and cisplatin-resistant progenitor phenotype in pediatric liver cancer. Cancer Discov. 11, 2524\u20132543 (2021).","journal-title":"Cancer Discov."},{"key":"1175_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42418-9","volume":"14","author":"J Pilet","year":"2023","unstructured":"Pilet, J. et al. Preneoplastic liver colonization by 11p15.5 altered mosaic cells in young children with hepatoblastoma. Nat. Commun. 14, 7122 (2023).","journal-title":"Nat. Commun."},{"key":"1175_CR61","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1126\/science.aab4082","volume":"349","author":"I Martincorena","year":"2015","unstructured":"Martincorena, I. & Campbell, P. J. Somatic mutation in cancer and normal cells. Science 349, 1483\u20131489 (2015).","journal-title":"Science"},{"key":"1175_CR62","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1126\/science.aaa6806","volume":"348","author":"I Martincorena","year":"2015","unstructured":"Martincorena, I. et al. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 348, 880\u2013886 (2015).","journal-title":"Science"},{"key":"1175_CR63","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41586-018-0811-x","volume":"565","author":"A Yokoyama","year":"2019","unstructured":"Yokoyama, A. et al. Age-related remodelling of oesophageal epithelia by mutated cancer drivers. Nature 565, 312\u2013317 (2019).","journal-title":"Nature"},{"key":"1175_CR64","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41586-025-08708-6","volume":"640","author":"THH Coorens","year":"2025","unstructured":"Coorens, T. H. H. et al. The somatic mutation landscape of normal gastric epithelium. Nature 640, 418\u2013426 (2025).","journal-title":"Nature"},{"key":"1175_CR65","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/s41586-019-1670-9","volume":"574","author":"SF Brunner","year":"2019","unstructured":"Brunner, S. F. et al. Somatic mutations and clonal dynamics in healthy and cirrhotic human liver. Nature 574, 538\u2013542 (2019).","journal-title":"Nature"},{"key":"1175_CR66","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41586-021-03974-6","volume":"598","author":"SWK Ng","year":"2021","unstructured":"Ng, S. W. K. et al. Convergent somatic mutations in metabolism genes in chronic liver disease. Nature 598, 473\u2013478 (2021).","journal-title":"Nature"},{"key":"1175_CR67","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1016\/j.cell.2023.03.014","volume":"186","author":"Z Wang","year":"2023","unstructured":"Wang, Z. et al. Positive selection of somatically mutated clones identifies adaptive pathways in metabolic liver disease. Cell 186, 1968\u20131984.e20 (2023).","journal-title":"Cell"},{"key":"1175_CR68","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/s41588-025-02125-1","volume":"57","author":"N Brzozowska","year":"2025","unstructured":"Brzozowska, N. et al. Selection for somatic escape variants in SERPINA1 in the liver of patients with alpha-1 antitrypsin deficiency. Nat. Genet. 57, 875\u2013883 (2025).","journal-title":"Nat. Genet."},{"key":"1175_CR69","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488\u20132498 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1175_CR70","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/nm.3733","volume":"20","author":"M Xie","year":"2014","unstructured":"Xie, M. et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat. Med. 20, 1472\u20131478 (2014).","journal-title":"Nat. Med."},{"key":"1175_CR71","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","volume":"371","author":"G Genovese","year":"2014","unstructured":"Genovese, G. et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 371, 2477\u20132487 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1175_CR72","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","volume":"377","author":"S Jaiswal","year":"2017","unstructured":"Jaiswal, S. et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N. Engl. J. Med. 377, 111\u2013121 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1175_CR73","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/s41586-023-05857-4","volume":"616","author":"WJ Wong","year":"2023","unstructured":"Wong, W. J. et al. Clonal haematopoiesis and risk of chronic liver disease. Nature 616, 747\u2013754 (2023).","journal-title":"Nature"},{"key":"1175_CR74","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1097\/HEP.0000000000000839","volume":"80","author":"A Marchetti","year":"2024","unstructured":"Marchetti, A. et al. Impact of clonal hematopoiesis of indeterminate potential on hepatocellular carcinoma in individuals with steatotic liver disease. Hepatology 80, 816\u2013827 (2024).","journal-title":"Hepatology"},{"key":"1175_CR75","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.jhep.2012.02.035","volume":"57","author":"P Nahon","year":"2012","unstructured":"Nahon, P. & Zucman-Rossi, J. Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosis. J. Hepatol. 57, 663\u2013674 (2012).","journal-title":"J. Hepatol."},{"key":"1175_CR76","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1002\/hep.26767","volume":"59","author":"E Tr\u00e9po","year":"2014","unstructured":"Tr\u00e9po, E. et al. Association between the PNPLA3 (rs738409 C\u2009>\u2009G) variant and hepatocellular carcinoma: evidence from a meta-analysis of individual participant data. Hepatology 59, 2170\u20132177 (2014).","journal-title":"Hepatology"},{"key":"1175_CR77","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/s41395-018-0041-8","volume":"113","author":"F Stickel","year":"2018","unstructured":"Stickel, F. et al. Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis. Am. J. Gastroenterol. 113, 1475\u20131483 (2018).","journal-title":"Am. J. Gastroenterol."},{"key":"1175_CR78","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/ijc.31910","volume":"144","author":"J Yang","year":"2019","unstructured":"Yang, J. et al. PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases. Int. J. Cancer 144, 533\u2013544 (2019).","journal-title":"Int. J. Cancer"},{"key":"1175_CR79","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.dld.2012.05.006","volume":"44","author":"MA Burza","year":"2012","unstructured":"Burza, M. A. et al. PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals. Dig. Liver Dis. 44, 1037\u20131041 (2012).","journal-title":"Dig. Liver Dis."},{"key":"1175_CR80","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jhep.2014.02.030","volume":"61","author":"YL Liu","year":"2014","unstructured":"Liu, Y. L. et al. Carriage of the PNPLA3 rs738409 C\u2009>\u2009G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J. Hepatol. 61, 75\u201381 (2014).","journal-title":"J. Hepatol."},{"key":"1175_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-04991-0","volume":"7","author":"B Donati","year":"2017","unstructured":"Donati, B. et al. MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. Sci. Rep. 7, 4492 (2017).","journal-title":"Sci. Rep."},{"key":"1175_CR82","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/apt.70256","volume":"62","author":"M Kubina","year":"2025","unstructured":"Kubina, M. et al. Meta-analysis: effects of steatotic liver disease-associated genetic risk alleles on longitudinal outcomes. Aliment. Pharmacol. Ther. 62, 244\u2013276 (2025).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1175_CR83","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/hep.30623","volume":"70","author":"J Yang","year":"2019","unstructured":"Yang, J. et al. A 17-beta-hydroxysteroid dehydrogenase 13 variant protects from hepatocellular carcinoma development in alcoholic liver disease. Hepatology 70, 231\u2013240 (2019).","journal-title":"Hepatology"},{"key":"1175_CR84","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/apt.17638","volume":"58","author":"H Innes","year":"2023","unstructured":"Innes, H., Morgan, M. Y., Hampe, J., Stickel, F. & Buch, S. The rs72613567:TA polymorphism in HSD17B13 is associated with survival benefit after development of hepatocellular carcinoma. Aliment. Pharmacol. Ther. 58, 623\u2013631 (2023).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1175_CR85","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.jhep.2022.03.031","volume":"77","author":"GA Baselli","year":"2022","unstructured":"Baselli, G. A. et al. Rare ATG7 genetic variants predispose patients to severe fatty liver disease. J. Hepatol. 77, 596\u2013606 (2022).","journal-title":"J. Hepatol."},{"key":"1175_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-39998-2","volume":"9","author":"S Pelusi","year":"2019","unstructured":"Pelusi, S. et al. Rare pathogenic variants predispose to hepatocellular carcinoma in nonalcoholic fatty liver disease. Sci. Rep. 9, 3682 (2019).","journal-title":"Sci. Rep."},{"key":"1175_CR87","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1111\/liv.14616","volume":"40","author":"H Chen","year":"2020","unstructured":"Chen, H. et al. Genetic variant rs72613567 of HSD17B13 gene reduces alcohol-related liver disease risk in Chinese Han population. Liver Int. 40, 2194\u20132202 (2020).","journal-title":"Liver Int."},{"key":"1175_CR88","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s12072-018-9889-3","volume":"12","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y. et al. Single-nucleotide rs738409 polymorphisms in the PNPLA3 gene are strongly associated with alcoholic liver disease in Han Chinese males. Hepatol. Int. 12, 429\u2013437 (2018).","journal-title":"Hepatol. Int."},{"key":"1175_CR89","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/HEP.0000000000000800","volume":"80","author":"MM Hassan","year":"2024","unstructured":"Hassan, M. M. et al. Genome-wide association study identifies high-impact susceptibility loci for HCC in North America. Hepatology 80, 87\u2013101 (2024).","journal-title":"Hepatology"},{"key":"1175_CR90","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/hep.22734","volume":"49","author":"V Paradis","year":"2009","unstructured":"Paradis, V. et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 49, 851\u2013859 (2009).","journal-title":"Hepatology"},{"key":"1175_CR91","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S1470-2045(21)00603-3","volume":"23","author":"E Tr\u00e9po","year":"2022","unstructured":"Tr\u00e9po, E. et al. Common genetic variation in alcohol-related hepatocellular carcinoma: a case\u2013control genome-wide association study. Lancet Oncol. 23, 161\u2013171 (2022).","journal-title":"Lancet Oncol."},{"key":"1175_CR92","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1136\/gutjnl-2022-327196","volume":"72","author":"S Buch","year":"2023","unstructured":"Buch, S. et al. Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case\u2013control study. Gut 72, 381\u2013391 (2023).","journal-title":"Gut"},{"key":"1175_CR93","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/HEP.0000000000000637","volume":"81","author":"C-W Chang","year":"2025","unstructured":"Chang, C.-W. et al. A genetic basis of mitochondrial DNAJA3 in nonalcoholic steatohepatitis-related hepatocellular carcinoma. Hepatology 81, 60\u201376\u00a0(2025).","journal-title":"Hepatology"},{"key":"1175_CR94","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/S1542-3565(04)00718-9","volume":"3","author":"P Nahon","year":"2005","unstructured":"Nahon, P. et al. Genetic dimorphism in superoxide dismutase and susceptibility to alcoholic cirrhosis, hepatocellular carcinoma, and death. Clin. Gastroenterol. Hepatol. 3, 292\u2013298 (2005).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1175_CR95","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1158\/1055-9965.EPI-11-0341","volume":"20","author":"F Charni","year":"2011","unstructured":"Charni, F. et al. Chemokine RANTES promoter dimorphisms and hepatocellular carcinoma occurrence in patients with alcoholic or hepatitis C virus-related cirrhosis. Cancer Epidemiol. Biomarkers Prev. 20, 1439\u20131446 (2011).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"1175_CR96","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1002\/ijc.21583","volume":"118","author":"N Homann","year":"2006","unstructured":"Homann, N. et al. Alcohol dehydrogenase 1C*1 allele is a genetic marker for alcohol-associated cancer in heavy drinkers. Int. J. Cancer 118, 1998\u20132002 (2006).","journal-title":"Int. J. Cancer"},{"key":"1175_CR97","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1002\/ijc.21505","volume":"118","author":"T Sakamoto","year":"2006","unstructured":"Sakamoto, T. et al. Influence of alcohol consumption and gene polymorphisms of ADH2 and ALDH2 on hepatocellular carcinoma in a Japanese population. Int. J. Cancer 118, 1501\u20131507 (2006).","journal-title":"Int. J. Cancer"},{"key":"1175_CR98","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s00432-003-0439-5","volume":"129","author":"M Munaka","year":"2003","unstructured":"Munaka, M. et al. Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and the risk of hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 129, 355\u2013360 (2003).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"1175_CR99","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41575-019-0229-4","volume":"17","author":"AJ Craig","year":"2020","unstructured":"Craig, A. J., von Felden, J., Garcia-Lezana, T., Sarcognato, S. & Villanueva, A. Tumour evolution in hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 17, 139\u2013152 (2020).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1175_CR100","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1053\/j.gastro.2009.07.037","volume":"137","author":"KL Rudolph","year":"2009","unstructured":"Rudolph, K. L., Hartmann, D. & Opitz, O. G. Telomere dysfunction and DNA damage checkpoints in diseases and cancer of the gastrointestinal tract. Gastroenterology 137, 754\u2013762 (2009).","journal-title":"Gastroenterology"},{"key":"1175_CR101","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/hep.20308","volume":"40","author":"A Satyanarayana","year":"2004","unstructured":"Satyanarayana, A., Manns, M. P. & Rudolph, K. L. Telomeres and telomerase: a dual role in hepatocarcinogenesis. Hepatology 40, 276\u2013283 (2004).","journal-title":"Hepatology"},{"key":"1175_CR102","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41575-019-0165-3","volume":"16","author":"J-C Nault","year":"2019","unstructured":"Nault, J.-C., Ningarhari, M., Rebouissou, S. & Zucman-Rossi, J. The role of telomeres and telomerase in cirrhosis and liver cancer. Nat. Rev. Gastroenterol. Hepatol. 16, 544\u2013558 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1175_CR103","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/ng0198-65","volume":"18","author":"J Nakayama","year":"1998","unstructured":"Nakayama, J. et al. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat. Genet. 18, 65\u201368 (1998).","journal-title":"Nat. Genet."},{"key":"1175_CR104","first-page":"5021","volume":"63","author":"PA Farazi","year":"2003","unstructured":"Farazi, P. A. et al. Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma. Cancer Res. 63, 5021\u20135027 (2003).","journal-title":"Cancer Res."},{"key":"1175_CR105","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41576-019-0099-1","volume":"20","author":"JW Shay","year":"2019","unstructured":"Shay, J. W. & Wright, W. E. Telomeres and telomerase: three decades of progress. Nat. Rev. Genet. 20, 299\u2013309 (2019).","journal-title":"Nat. Rev. Genet."},{"key":"1175_CR106","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1001\/jamainternmed.2021.7804","volume":"182","author":"CV Schneider","year":"2022","unstructured":"Schneider, C. V. et al. Association of telomere length with risk of disease and mortality. JAMA Intern. Med. 182, 291\u2013300 (2022).","journal-title":"JAMA Intern. Med."},{"key":"1175_CR107","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.jhep.2020.11.052","volume":"74","author":"M Ningarhari","year":"2021","unstructured":"Ningarhari, M. et al. Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target. J. Hepatol. 74, 1155\u20131166 (2021).","journal-title":"J. Hepatol."},{"key":"1175_CR108","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0140-6736(03)12384-7","volume":"361","author":"RM Cawthon","year":"2003","unstructured":"Cawthon, R. M., Smith, K. R., O\u2019Brien, E., Sivatchenko, A. & Kerber, R. A. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet 361, 393\u2013395 (2003).","journal-title":"Lancet"},{"key":"1175_CR109","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.exger.2013.12.004","volume":"51","author":"M Gardner","year":"2014","unstructured":"Gardner, M. et al. Gender and telomere length: systematic review and meta-analysis. Exp. Gerontol. 51, 15\u201327 (2014).","journal-title":"Exp. Gerontol."},{"key":"1175_CR110","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/jop.12947","volume":"49","author":"J Aida","year":"2020","unstructured":"Aida, J. et al. Telomere shortening in the oral epithelium in relation to alcohol intake, alcohol dehydrogenase (ADH-1B), and acetaldehyde dehydrogenase (ALDH-2) genotypes and clinicopathologic features. J. Oral Pathol. Med. 49, 82\u201390 (2020).","journal-title":"J. Oral Pathol. Med."},{"key":"1175_CR111","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","volume":"349","author":"T Poynard","year":"1997","unstructured":"Poynard, T., Bedossa, P. & Opolon, P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 349, 825\u2013832 (1997).","journal-title":"Lancet"},{"key":"1175_CR112","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1002\/hep.24217","volume":"53","author":"D Hartmann","year":"2011","unstructured":"Hartmann, D. et al. Telomerase gene mutations are associated with cirrhosis formation. Hepatology 53, 1608\u20131617 (2011).","journal-title":"Hepatology"},{"key":"1175_CR113","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1002\/hep.24173","volume":"53","author":"RT Calado","year":"2011","unstructured":"Calado, R. T. et al. Constitutional telomerase mutations are genetic risk factors for cirrhosis. Hepatology 53, 1600\u20131607 (2011).","journal-title":"Hepatology"},{"key":"1175_CR114","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1002\/cam4.1078","volume":"6","author":"B Donati","year":"2017","unstructured":"Donati, B. et al. Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. Cancer Med. 6, 1930\u20131940 (2017).","journal-title":"Cancer Med."},{"key":"1175_CR115","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1096\/fj.01-0977com","volume":"16","author":"SU Wiemann","year":"2002","unstructured":"Wiemann, S. U. et al. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J. 16, 935\u201342 (2002).","journal-title":"FASEB J."},{"key":"1175_CR116","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1038\/ncomms3218","volume":"4","author":"JC Nault","year":"2013","unstructured":"Nault, J.-C. et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat. Commun. 4, 2218 (2013).","journal-title":"Nat. Commun."},{"key":"1175_CR117","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1002\/hep.27372","volume":"60","author":"J-C Nault","year":"2014","unstructured":"Nault, J.-C. et al. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology 60, 1983\u20131992 (2014).","journal-title":"Hepatology"},{"key":"1175_CR118","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/ng.3126","volume":"46","author":"Y Totoki","year":"2014","unstructured":"Totoki, Y. et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat. Genet. 46, 1267\u20131273 (2014).","journal-title":"Nat. Genet."},{"key":"1175_CR119","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1038\/sj.onc.1206492","volume":"22","author":"P Paterlini-Br\u00e9chot","year":"2003","unstructured":"Paterlini-Br\u00e9chot, P. et al. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene 22, 3911\u20133916 (2003).","journal-title":"Oncogene"},{"key":"1175_CR120","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2017.08.013","volume":"67","author":"S Torrecilla","year":"2017","unstructured":"Torrecilla, S. et al. Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma. J. Hepatol. 67, 1222\u20131231 (2017).","journal-title":"J. Hepatol."},{"key":"1175_CR121","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415\u2013421 (2013).","journal-title":"Nature"},{"key":"1175_CR122","first-page":"763","volume":"30","author":"S Nik-Zainal","year":"2015","unstructured":"Nik-Zainal, S. et al. The genome as a record of environmental exposure. Mutagenesis 30, 763\u201370 (2015).","journal-title":"Mutagenesis"},{"key":"1175_CR123","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/ng.3252","volume":"47","author":"K Schulze","year":"2015","unstructured":"Schulze, K. et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat. Genet. 47, 505\u2013511 (2015).","journal-title":"Nat. Genet."},{"key":"1175_CR124","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01358-x","volume":"8","author":"E Letouz\u00e9","year":"2017","unstructured":"Letouz\u00e9, E. et al. Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis. Nat. Commun. 8, 1315 (2017).","journal-title":"Nat. Commun."},{"key":"1175_CR125","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.jhep.2021.04.049","volume":"75","author":"R Pinyol","year":"2021","unstructured":"Pinyol, R. et al. Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J. Hepatol. 75, 865\u2013878 (2021).","journal-title":"J. Hepatol."},{"key":"1175_CR126","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1053\/j.gastro.2018.11.001","volume":"156","author":"R Dhanasekaran","year":"2019","unstructured":"Dhanasekaran, R., Nault, J.-C., Roberts, L. R. & Zucman-Rossi, J. Genomic medicine and implications for hepatocellular carcinoma prevention and therapy. Gastroenterology 156, 492\u2013509 (2019).","journal-title":"Gastroenterology"},{"key":"1175_CR127","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/ng.2256","volume":"44","author":"C Guichard","year":"2012","unstructured":"Guichard, C. et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat. Genet. 44, 694\u2013698 (2012).","journal-title":"Nat. Genet."},{"key":"1175_CR128","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.cell.2017.05.046","volume":"169","author":"A Ally","year":"2017","unstructured":"Ally, A. et al. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 169, 1327\u20131341.e23 (2017).","journal-title":"Cell"},{"key":"1175_CR129","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/hep.21467","volume":"45","author":"S Boyault","year":"2007","unstructured":"Boyault, S. et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45, 42\u201352 (2007).","journal-title":"Hepatology"},{"key":"1175_CR130","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jhep.2019.08.017","volume":"72","author":"S Rebouissou","year":"2020","unstructured":"Rebouissou, S. & Nault, J.-C. Advances in molecular classification and precision oncology in hepatocellular carcinoma. J. Hepatol. 72, 215\u2013229 (2020).","journal-title":"J. Hepatol."},{"key":"1175_CR131","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1097\/PAS.0000000000001533","volume":"44","author":"J Qin","year":"2020","unstructured":"Qin, J. et al. Steatohepatitic variant of hepatocellular carcinoma is associated with both alcoholic steatohepatitis and nonalcoholic steatohepatitis: a study of 2 cohorts with molecular insights. Am. J. Surg. Pathol. 44, 1406\u20131412 (2020).","journal-title":"Am. J. Surg. Pathol."},{"key":"1175_CR132","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1097\/PAS.0b013e3181f31caa","volume":"34","author":"M Salomao","year":"2010","unstructured":"Salomao, M., Yu, W. M., Brown, R. S., Emond, J. C. & Lefkowitch, J. H. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD\/NASH. Am. J. Surg. Pathol. 34, 1630\u20131636 (2010).","journal-title":"Am. J. Surg. Pathol."},{"key":"1175_CR133","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jhep.2017.05.014","volume":"67","author":"J Calderaro","year":"2017","unstructured":"Calderaro, J. et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J. Hepatol. 67, 727\u2013738 (2017).","journal-title":"J. Hepatol."},{"key":"1175_CR134","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0171922","volume":"12","author":"JS Lee","year":"2017","unstructured":"Lee, J. S. et al. Tumor stroma with senescence-associated secretory phenotype in steatohepatitic hepatocellular carcinoma. PLoS ONE 12, e0171922 (2017).","journal-title":"PLoS ONE"},{"key":"1175_CR135","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/ajcp\/aqaa114","volume":"155","author":"BJ Van Treeck","year":"2021","unstructured":"Van Treeck, B. J. et al. Transcriptomic and proteomic analysis of steatohepatitic hepatocellular carcinoma reveals novel distinct biologic features. Am. J. Clin. Pathol. 155, 87\u201396 (2021).","journal-title":"Am. J. Clin. Pathol."},{"key":"1175_CR136","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1136\/gutjnl-2017-315193","volume":"67","author":"N Fujiwara","year":"2018","unstructured":"Fujiwara, N. et al. CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity. Gut 67, 1493\u20131504 (2018).","journal-title":"Gut"},{"key":"1175_CR137","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1002\/hep.27198","volume":"60","author":"S-M Ahn","year":"2014","unstructured":"Ahn, S.-M. et al. A genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology 60, 1972\u20131982\u00a0(2014).","journal-title":"Hepatology"},{"key":"1175_CR138","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1136\/gutjnl-2013-306228","volume":"64","author":"G Amaddeo","year":"2015","unstructured":"Amaddeo, G. et al. Integration of tumour and viral genomic characterisations in HBV-related hepatocellular carcinomas. Gut 64, 820\u2013829 (2015).","journal-title":"Gut"},{"key":"1175_CR139","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/HEP.0000000000000591","volume":"79","author":"M Li","year":"2024","unstructured":"Li, M. et al. Spatial proteomics of immune microenvironment in nonalcoholic steatohepatitis-associated hepatocellular carcinoma. Hepatology 79, 560\u2013574 (2024).","journal-title":"Hepatology"},{"key":"1175_CR140","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/hep.30212","volume":"69","author":"Y Inada","year":"2019","unstructured":"Inada, Y. et al. Characteristics of immune response to tumor-associated antigens and immune cell profile in patients with hepatocellular carcinoma. Hepatology 69, 653\u2013665 (2019).","journal-title":"Hepatology"},{"key":"1175_CR141","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nature16969","volume":"531","author":"C Ma","year":"2016","unstructured":"Ma, C. et al. NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis. Nature 531, 253\u2013257 (2016).","journal-title":"Nature"},{"key":"1175_CR142","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","volume":"592","author":"D Pfister","year":"2021","unstructured":"Pfister, D. et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 592, 450\u2013456 (2021).","journal-title":"Nature"},{"key":"1175_CR143","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/j.jhep.2023.04.012","volume":"79","author":"T Meyer","year":"2023","unstructured":"Meyer, T., Galani, S., Lopes, A. & Vogel, A. Aetiology of liver disease and response to immune checkpoint inhibitors: an updated meta-analysis confirms benefit in those with non-viral liver disease. J. Hepatol. 79, e73\u2013e76 (2023).","journal-title":"J. Hepatol."},{"key":"1175_CR144","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1053\/j.gastro.2021.06.008","volume":"161","author":"PK Haber","year":"2021","unstructured":"Haber, P. K. et al. Evidence-based management of hepatocellular carcinoma: systematic review and meta-analysis of randomized controlled trials (2002\u20132020). Gastroenterology 161, 879\u2013898 (2021).","journal-title":"Gastroenterology"},{"key":"1175_CR145","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ajhg.2022.12.011","volume":"110","author":"A Abdellaoui","year":"2023","unstructured":"Abdellaoui, A., Yengo, L., Verweij, K. J. H. & Visscher, P. M. 15 years of GWAS discovery: realizing the promise. Am. J. Hum. Genet. 110, 179\u2013194 (2023).","journal-title":"Am. J. Hum. Genet."},{"key":"1175_CR146","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41576-018-0018-x","volume":"19","author":"A Torkamani","year":"2018","unstructured":"Torkamani, A., Wineinger, N. E. & Topol, E. J. The personal and clinical utility of polygenic risk scores. Nat. Rev. Genet. 19, 581\u2013590 (2018).","journal-title":"Nat. Rev. Genet."},{"key":"1175_CR147","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41576-022-00470-z","volume":"23","author":"IJ Kullo","year":"2022","unstructured":"Kullo, I. J. et al. Polygenic scores in biomedical research. Nat. Rev. Genet. 23, 524\u2013532 (2022).","journal-title":"Nat. Rev. Genet."},{"key":"1175_CR148","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s41591-024-02796-z","volume":"30","author":"NJ Lennon","year":"2024","unstructured":"Lennon, N. J. et al. Selection, optimization and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse US populations. Nat. Med. 30, 480\u2013487 (2024).","journal-title":"Nat. Med."},{"key":"1175_CR149","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1001\/jama.2025.0621","volume":"333","author":"SA Abramowitz","year":"2025","unstructured":"Abramowitz, S. A., Levin, M. G. & Damrauer, S. M. Performance and agreement of coronary heart disease polygenic risk scores-reply. JAMA 333, 1548\u20131549 (2025).","journal-title":"JAMA"},{"key":"1175_CR150","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-021-03243-6","volume":"591","author":"H Wand","year":"2021","unstructured":"Wand, H. et al. Improving reporting standards for polygenic scores in risk prediction studies. Nature 591, 211\u2013219 (2021).","journal-title":"Nature"},{"key":"1175_CR151","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-073149","volume":"380","author":"A Sud","year":"2023","unstructured":"Sud, A. et al. Realistic expectations are key to realising the benefits of polygenic scores. BMJ 380, e073149 (2023).","journal-title":"BMJ"},{"key":"1175_CR152","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jhep.2022.11.003","volume":"78","author":"P Nahon","year":"2022","unstructured":"Nahon, P. et al. Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis. J. Hepatol.\u00a078, 584\u2013595 (2022).","journal-title":"J. Hepatol."},{"key":"1175_CR153","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.jhep.2023.05.005","volume":"79","author":"H Innes","year":"2023","unstructured":"Innes, H. & Nahon, P. Statistical perspectives on using hepatocellular carcinoma risk models to inform surveillance decisions. J. Hepatol. 79, 1332\u20131337 (2023).","journal-title":"J. Hepatol."},{"key":"1175_CR154","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jhep.2022.02.022","volume":"77","author":"H Innes","year":"2022","unstructured":"Innes, H. et al. Performance of routine risk scores for predicting cirrhosis-related morbidity in the community. J. Hepatol. 77, 365\u2013376 (2022).","journal-title":"J. Hepatol."},{"key":"1175_CR155","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00280-w","volume":"6","author":"AJ Vickers","year":"2022","unstructured":"Vickers, A. J., Sud, A., Bernstein, J. & Houlston, R. Polygenic risk scores to stratify cancer screening should predict mortality not incidence. npj Precis. Oncol. 6, 32 (2022).","journal-title":"npj Precis. Oncol."},{"key":"1175_CR156","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41576-022-00571-9","volume":"24","author":"P Lacaze","year":"2023","unstructured":"Lacaze, P., Manchanda, R. & Green, R. C. Prioritizing the detection of rare pathogenic variants in population screening. Nat. Rev. Genet. 24, 205\u2013206 (2023).","journal-title":"Nat. Rev. Genet."},{"key":"1175_CR157","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(23)02295-X","volume":"403","author":"C Turnbull","year":"2024","unstructured":"Turnbull, C. et al. Population screening requires robust evidence \u2014 genomics is no exception. Lancet 403, 583\u2013586 (2024).","journal-title":"Lancet"},{"key":"1175_CR158","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1038\/s41591-024-03483-9","volume":"31","author":"MA Argentieri","year":"2025","unstructured":"Argentieri, M. A. et al. Integrating the environmental and genetic architectures of aging and mortality. Nat. Med. 31, 1016\u20131025 (2025).","journal-title":"Nat. Med."},{"key":"1175_CR159","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41562-019-0562-1","volume":"3","author":"DW Belsky","year":"2019","unstructured":"Belsky, D. W. et al. Genetics and the geography of health, behaviour and attainment. Nat. Hum. Behav. 3, 576\u2013586 (2019).","journal-title":"Nat. Hum. Behav."},{"key":"1175_CR160","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/s41588-019-0379-x","volume":"51","author":"AR Martin","year":"2019","unstructured":"Martin, A. R. et al. Clinical use of current polygenic risk scores may exacerbate health disparities. Nat. Genet. 51, 584\u2013591 (2019).","journal-title":"Nat. Genet."},{"key":"1175_CR161","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41575-025-01108-1","volume":"22","author":"IC Wiest","year":"2025","unstructured":"Wiest, I. C. et al. Large language models for clinical decision support in gastroenterology and hepatology. Nat. Rev. Gastroenterol. Hepatol. 22, 773\u2013787\u00a0(2025).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1175_CR162","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41568-024-00694-7","volume":"24","author":"R Perez-Lopez","year":"2024","unstructured":"Perez-Lopez, R., Ghaffari Laleh, N., Mahmood, F. & Kather, J. N. A guide to artificial intelligence for cancer researchers. Nat. Rev. Cancer 24, 427\u2013441 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"1175_CR163","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.jhep.2025.07.003","volume":"83","author":"J Clusmann","year":"2025","unstructured":"Clusmann, J. et al. The barriers to uptake of artificial intelligence in hepatology and how to overcome them. J. Hepatol. 83, 1410\u20131426 (2025).","journal-title":"J. Hepatol."},{"key":"1175_CR164","doi-asserted-by":"crossref","unstructured":"The Lancet. Direct-to-consumer medical testing: an industry built on fear. Lancet 404, 991 (2024).","DOI":"10.1016\/S0140-6736(24)01924-X"},{"key":"1175_CR165","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.jhep.2021.12.015","volume":"76","author":"A Gardin","year":"2022","unstructured":"Gardin, A., Remih, K., Gonzales, E., Andersson, E. R. & Strnad, P. Modern therapeutic approaches to liver-related disorders. J. Hepatol. 76, 1392\u20131409 (2022).","journal-title":"J. Hepatol."},{"key":"1175_CR166","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.jhep.2023.05.007","volume":"79","author":"D Lind\u00e9n","year":"2023","unstructured":"Lind\u00e9n, D. & Romeo, S. Therapeutic opportunities for the treatment of NASH with genetically validated targets. J. Hepatol. 79, 1056\u20131064 (2023).","journal-title":"J. Hepatol."},{"key":"1175_CR167","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1056\/NEJMc2402341","volume":"391","author":"E Fabbrini","year":"2024","unstructured":"Fabbrini, E. et al. Phase 1 trials of PNPLA3 siRNA in I148M homozygous patients with MAFLD. N. Engl. J. Med. 391, 475\u2013476 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1175_CR168","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41586-023-06388-8","volume":"620","author":"K Trajanoska","year":"2023","unstructured":"Trajanoska, K. et al. From target discovery to clinical drug development with human genetics. Nature 620, 737\u2013745 (2023).","journal-title":"Nature"},{"key":"1175_CR169","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-01084-2","author":"A Do","year":"2024","unstructured":"Do, A., Zahrawi, F. & Mehal, W. Z. Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH). Nat. Rev. Drug Discov. https:\/\/doi.org\/10.1038\/s41573-024-01084-2 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1175_CR170","doi-asserted-by":"publisher","unstructured":"Zimmermann, A. in Tumors and Tumor-Like Lesions of the Hepatobiliary Tract https:\/\/doi.org\/10.1007\/978-3-319-26587-2_10-1 (Springer, 2016).","DOI":"10.1007\/978-3-319-26587-2_10-1"},{"key":"1175_CR171","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41588-021-00783-5","volume":"53","author":"SA Lambert","year":"2021","unstructured":"Lambert, S. A. et al. The Polygenic Score Catalog as an open database for reproducibility and systematic evaluation. Nat. Genet. 53, 420\u2013425 (2021).","journal-title":"Nat. Genet."}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01175-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01175-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01175-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T12:02:24Z","timestamp":1780401744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01175-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":171,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1175"],"URL":"https:\/\/doi.org\/10.1038\/s41575-026-01175-y","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"19 January 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.T. received honoraria, support for travel and attending meetings from Gilead. J.-C.N. received a research grant from Bayer and Ipsen.\u00a0J.Z.-R. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}